Primary hyperaldosteronism surgery

Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Primary hyperaldosteronism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Primary Hyperaldosteronism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

CT scan Findings

MRI Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Case Studies

Case #1

Primary hyperaldosteronism surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Primary hyperaldosteronism surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Primary hyperaldosteronism surgery

CDC on Primary hyperaldosteronism surgery

Primary hyperaldosteronism surgery in the news

Blogs on Primary hyperaldosteronism surgery

Directions to Hospitals Treating Conn syndrome

Risk calculators and risk factors for Primary hyperaldosteronism surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]

Overview

Surgery is the mainstay of treatment for unilateral adrenal hyperplasia, aldosterone producing adenomas (APAs), adrenal carcinoma, ectopic ACTH, renin, and deoxycorticosterone secreting tumors.

Surgery

Adrenal lesions producing excess aldosterone are treated mainly by laparoscopic adrenalectomy. Retroperitoneoscopic removal of adrenal glands in patients with primary hyperaldosteronism (Conn's syndrome) is a safe, rapidly performed surgical procedure and can thus be considered as first choice option for treatment of both solitary adrenal adenomas and hyperplasia presenting with a clinically predominating nodule.[1] Symptom resolution may take one to six months after the procedure.

Indications

Surgery for primary hyperaldosteronism is indicated in the following:[2]

Biochemical evidence of primary aldosteronism,. defined as all of the following present[3]:

  • plasma aldosterone concentration ≥15 ng/dL
  • aldosterone-renin activity ratio ≥30 or aldosterone-renin concentration ratio ≥4.8
  • suppressed renin

Contraindications

Surgery is contraindicated in the following situations:

Post-surgical management

Postoperative management of primary hyperaldosteronism includes the following:[4]

  • PRN use of anti-hypertensives and anti-hypokalemics
  • Anti-hypokalemia can be continued if serum potassium is <3.0 meq/l
  • PAC/PRA should be recorded immediately postoperatively on day one, to ensure surgical cure.
  • Intra-venous saline load test (SLT) or a fludrocortisone suppression test (FST) can be conducted three months after surgery.

Post Surgical Prognosis

Good prognosis after adrenalectomy depends on:[5]

References

  1. Walz MK, Gwosdz R, Levin SL, Alesina PF, Suttorp AC, Metz KA, Wenger FA, Petersenn S, Mann K, Schmid KW (2008). "Retroperitoneoscopic adrenalectomy in Conn's syndrome caused by adrenal adenomas or nodular hyperplasia". World J Surg. 32 (5): 847–53. doi:10.1007/s00268-008-9513-0. PMID 18343972.
  2. Horsley MG, Bailie GR (1988). "Effectiveness of theophylline monitoring by the use of serum assays". J Clin Pharm Ther. 13 (5): 359–64. PMID 3230101.
  3. Cohen JB, Cohen DL, Herman DS, Leppert JT, Byrd JB, Bhalla V (2020). "Testing for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among U.S. Veterans : A Retrospective Cohort Study". Ann Intern Med. doi:10.7326/M20-4873. PMID 33370170 Check |pmid= value (help).
  4. Horsley MG, Bailie GR (1988). "Effectiveness of theophylline monitoring by the use of serum assays". J Clin Pharm Ther. 13 (5): 359–64. PMID 3230101.
  5. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF, Montori VM (2008). "Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline". J. Clin. Endocrinol. Metab. 93 (9): 3266–81. doi:10.1210/jc.2008-0104. PMID 18552288.

Template:WH Template:WS